These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 34853646)
1. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. Deng Z; Teng YJ; Zhou Q; Ouyang ZG; Hu YX; Long HP; Hu MJ; Mei S; Lin FX; Dai XJ; Zhang BY; Feng T; Tian XF World J Gastrointest Oncol; 2021 Nov; 13(11):1725-1740. PubMed ID: 34853646 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability. Qiu J; Zhong F; Zhang Z; Pan B; Ye D; Zhang X; Yao Y; Luo Y; Wang X; Tang N Int Immunopharmacol; 2024 Jul; 136():112415. PubMed ID: 38850791 [TBL] [Abstract][Full Text] [Related]
3. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway. Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877 [TBL] [Abstract][Full Text] [Related]
4. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression. Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678 [TBL] [Abstract][Full Text] [Related]
5. Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma. Chen ZQ; Zuo XL; Cai J; Zhang Y; Han GY; Zhang L; Ding WZ; Wu JD; Wang XH Exp Hematol Oncol; 2023 Feb; 12(1):17. PubMed ID: 36747292 [TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
7. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo. Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447 [TBL] [Abstract][Full Text] [Related]
8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
9. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer. Zhang YF; Zhang ZH; Li MY; Wang JY; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Zuo HX; Jin HL; Ma J; Jin X Phytomedicine; 2021 Jan; 81():153425. PubMed ID: 33310309 [TBL] [Abstract][Full Text] [Related]
10. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment. Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707 [TBL] [Abstract][Full Text] [Related]
11. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Chang YL; Yang CY; Lin MW; Wu CT; Yang PC Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327 [TBL] [Abstract][Full Text] [Related]
12. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma. Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999 [TBL] [Abstract][Full Text] [Related]
13. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation. Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance. Wang X; Ye X; Chen Y; Lin J Int Immunopharmacol; 2023 Nov; 124(Pt A):110848. PubMed ID: 37633233 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110 [TBL] [Abstract][Full Text] [Related]
16. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression. Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808 [TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor-1α inhibition augments efficacy of programmed cell death 1 antibody in murine prostatic cancer models. Shen Z; Pei Q; Zhang H; Yang C; Cui H; Li B; Liu J; Bo Z; Wei F; Zhang M; Liu C Anticancer Drugs; 2022 Jul; 33(6):587-594. PubMed ID: 35324523 [TBL] [Abstract][Full Text] [Related]
19. Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma. Kang J; Zheng Z; Li X; Huang T; Rong D; Liu X; Qin M; Wang Y; Kong X; Song J; Lv C; Pan X Cancer Cell Int; 2022 Oct; 22(1):312. PubMed ID: 36224624 [TBL] [Abstract][Full Text] [Related]
20. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Wang Z; Li MY; Zhang ZH; Zuo HX; Wang JY; Xing Y; Ri M; Jin HL; Jin CH; Xu GH; Piao LX; Jiang CG; Ma J; Jin X Pharmacol Res; 2020 May; 155():104727. PubMed ID: 32113874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]